While Vertex talked of 80% [as the SVR goal], the Roche rep said North of 80% (perhaps just a slight wording difference) but maybe more to it.
The wording difference is of no consequence, IMO. For all practical purposes, Roche and VRTX are pursuing the same approach to all-oral combination therapy.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”